CMN Weekly (29 November 2024) - Your Weekly CRISPR...
CMN Weekly
Nov. 29, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Roche
Main focus: Therapeutic development and diagnostics for diverse disease areas
Company stage: Clinical
Diseases: Haematological malignancies, autoimmune disease, cardiovascular disease, metabolic disorders, ophthalmologic disease, neurological disorders, and infectious diseases
Genome-editing tool: Cas-CLOVER™ Site-Specific Gene-Editing System
Funding stage:
Location: Basel, Switzerland
Website: https://www.roche.com/
Pipeline: https://www.roche.com/solutions/pipeline
Partners: Roche has over 250 active global partnerships including Poseida Therapeutics.
Roche is a biotechnology company that specialises in pharmaceutical development and diagnostics. Roche focuses on therapeutics for several diseases including haematological malignancies, autoimmune disorders, infectious diseases, and neurological conditions. Roche has formed a global partnership with Poseida Therapeutics to develop novel therapies for patients with haematological malignancies. Their approach is built on Poseida's proprietary genetic-editing platforms, including the non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule, and nanoparticle and hybrid gene delivery technologies.
